Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: COMMENTARY.
作者信息
Mavrakanas Thomas A
机构信息
Division of Nephrology, Department of Medicine, McGill University Health Centre & Research Institute, Montreal, Canada.
出版信息
Kidney360. 2021 Apr 9;2(9):1412-1414. doi: 10.34067/KID.0001372021. eCollection 2021 Sep 30.
Abstract
摘要
相似文献
1
Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: COMMENTARY.终末期肾病血液透析合并心房颤动患者是否应使用口服抗凝药？：评论
Kidney360. 2021 Apr 9;2(9):1412-1414. doi: 10.34067/KID.0001372021. eCollection 2021 Sep 30.
2
Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.长期血液透析的心房颤动患者的口服抗凝治疗。
J Am Coll Cardiol. 2020 Jan 28;75(3):273-285. doi: 10.1016/j.jacc.2019.10.059.
3
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
4
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.非瓣膜性心房颤动患者的大出血并发症与口服抗凝治疗的持续性：丹麦真实患者的当代研究结果
J Am Heart Assoc. 2017 Feb 14;6(2):e004517. doi: 10.1161/JAHA.116.004517.
5
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.透析终末期肾病合并心房颤动患者的口服抗凝治疗。
Semin Nephrol. 2018 Nov;38(6):618-628. doi: 10.1016/j.semnephrol.2018.08.006.
6
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.非维生素 K 拮抗剂口服抗凝剂和华法林在心房颤动中的有效性和安全性：一项斯堪的纳维亚基于人群的队列研究。
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):577-587. doi: 10.1093/ehjqcco/qcab048.
7
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.丹麦抗凝初治心房颤动患者中应用非维生素 K 拮抗剂口服抗凝药物的全国描述性数据 2011-2013 年。
Europace. 2015 Feb;17(2):187-93. doi: 10.1093/europace/euu225. Epub 2014 Sep 18.
8
Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.利伐沙班与华法林用于非瓣膜性心房颤动且伴有严重肾脏疾病或正在接受血液透析的患者。
Am J Med. 2019 Sep;132(9):1078-1083. doi: 10.1016/j.amjmed.2019.04.013. Epub 2019 May 2.
9
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动虚弱患者中阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi: 10.1161/JAHA.118.008643.
10
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.一项关于慢性肾脏病和透析合并心房颤动患者使用直接口服抗凝剂的系统评价。
Nephrol Dial Transplant. 2019 Feb 1;34(2):265-277. doi: 10.1093/ndt/gfy031.
引用本文的文献
1
Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics.腹膜透析治疗终末期肾病对阿哌沙班药代动力学的影响。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1918-1920. doi: 10.1093/ndt/gfad087.
2
Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation.阿哌沙班与依替巴肽在透析伴房颤患者中的应用：P2Y12 抑制剂抗凝方案对预后的影响。
Kidney360. 2022 Aug 1;3(10):1769-1771. doi: 10.34067/KID.0003002022. eCollection 2022 Oct 27.
Zotero 插件